ADPT
Adaptive Biotechnologies Corporation
Stock
$28.35+0.98 (+3.58%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $308M | $277M | $179M | $170M | $185M | $154M | $98M | $85M | $56M | $38M |
| Cost of revenue | $75M | $71M | $72M | $76M | $58M | $49M | $23M | $22M | $20M | $16M |
| Gross profit | $233M | $206M | $107M | $95M | $127M | $105M | $76M | $63M | $36M | $23M |
| R&D | $88M | $94M | $103M | $122M | $142M | $142M | $116M | $71M | $39M | $32M |
| SG&A | $180M | $167M | $158M | $173M | $184M | $170M | $111M | $69M | $45M | $33M |
| Other operating expenses | $1.7M | $1.7M | $8.9M | $27M | $1.7M | $1.7M | $1.7M | $1.7M | $1.7M | $2.5M |
| Operating income | −$37M | −$57M | −$163M | −$227M | −$200M | −$209M | −$153M | −$78M | −$50M | −$44M |
| Non-operating income | — | −$2.3M | $3.0M | $1.7M | −$182K | $1.7M | $6.6M | $9.8M | — | — |
| Pretax income | — | −$59M | −$160M | −$225M | −$200M | −$207M | −$146M | −$69M | — | — |
| Taxes | — | $42K | −$103K | −$54K | −$177K | −$19K | $0 | $0 | — | — |
| Net income | −$64M | −$59M | −$159M | −$225M | −$200M | −$207M | −$146M | −$69M | −$46M | −$43M |
| Diluted EPS | −$0.42 | −$0.39 | −$1.08 | −$1.56 | −$1.40 | −$1.48 | −$1.11 | −$1.01 | −$3.67 | −$3.50 |
| Diluted shares | — | 151.7M | 147.1M | 144.4M | 142.5M | 140.4M | 131.2M | 69.2M | 12.6M | 12.2M |
| Revenue growth | — | +54.8% | +5.1% | −8.1% | +20.1% | +56.9% | +15.6% | +52.8% | +44.8% | — |
| Gross margin | 75.6% | 74.2% | 59.7% | 55.6% | 68.7% | 68.1% | 77.1% | 73.8% | 64.7% | 59.2% |
| Operating margin | −12.2% | −20.6% | −90.8% | −133.3% | −108.0% | −135.4% | −155.3% | −92.1% | −89.4% | −115.7% |
| Net margin | −20.7% | −21.5% | −89.1% | −132.3% | −108.0% | −134.3% | −148.6% | −80.6% | −83.4% | −111.4% |